Currently out of the existing stock ratings of Chad Mabry, 32 are a BUY (96.97%), 1 are a HOLD (3.03%).

Chad Mabry

Work Performance Price Targets & Ratings Chart

Analyst Chad Mabry, currently employed carries an average stock price target met ratio of 42.59% that have a potential upside of 17.05% achieved within 384 days. Previously, Chad Mabry worked at MLV.

Chad Mabry’s has documented 66 price targets and ratings displayed on 9 stocks. The coverage was on Energy, Healthcare sectors.

Most recent stock forecast was given on ALT, Altimmune at 07-Sep-2021.

Wall Street Analyst Chad Mabry

Analyst best performing recommendations are on QEP (QEP RESOURCES).
The best stock recommendation documented was for QEP (QEP RESOURCES) at 7/21/2016. The price target of $19 was fulfilled within 25 days with a profit of $2.06 (12.16%) receiving and performance score of 4.86.

Average potential price target upside

CPE Callon Petroleum Company CRZO Carrizo Oil & Gas ESTE Earthstone Energy GTBP GT Biopharma INMB INmune Bio ALT Altimmune MTDR Matador Resources Company QEP QEP Resources WPX WPX Energy

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Hold

$38

$2.24 (6.26%)

$60

8 months 13 days ago
(26-Feb-2024)

0/9 (0%)

$7.17 (23.26%)

Hold

$32

$-3.76 (-10.51%)

$44

9 months 16 days ago
(23-Jan-2024)

1/10 (10%)

$0.42 (1.33%)

1

Buy

$45

$9.24 (25.84%)

$51

10 months ago
(08-Jan-2024)

7/22 (31.82%)

$10.47 (30.32%)

44

Hold

$40

$4.24 (11.86%)

$41

11 months 10 days ago
(29-Nov-2023)

1/4 (25%)

$8.43 (26.70%)

45

$40

$4.24 (11.86%)

$41

11 months 10 days ago
(29-Nov-2023)

5/14 (35.71%)

$8.43 (26.70%)

30

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What Year was the first public recommendation made by Chad Mabry?

On 2014

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?